Published Online:21 Aug 2006https://doi.org/10.2217/14796694.2.4.449
Abstract
Surgery and radiotherapy are the standard treatment options for patients with squamous cell carcinoma of the head and neck (SCCHN). Chemotherapy and chemoradiotherapy are new alternatives for locally advanced disease, particularly induction chemotherapy for patients with unresectable tumors. In recurrent/metastatic disease and after progression to platin-based regimens, no treatments other than best supportive care are currently available. Most SCCHN tumors overexpress the epidermal growth factor receptor (EGFR). This is a tyrosine kinase membrane receptor and has a clear implication in angiogenesis, tumor progression and resistance to different cancer treatments. Cetuximab is a monoclonal antibody that binds to EGFR and alters the tyrosine kinase-mediated signal transduction pathway. The drug is active in colon cancer and is currently being tested in SCCHN patients. For locally advanced disease, cetuximab/radiotherapy combination has demonstrated a benefit in survival when compared with radiotherapy alone as radical treatment. Cetuximab is an active treatment in platin-refractory patients with recurrent/metastatic disease.
Keywords:
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Vokes EE, Weichselbaum R, Lippman S, Hong W: Head and neck cancer. N. Engl. J. Med.328,184–194 (1993).•• Extensive review of the clinical characteristics of head and neck cancer.
- 2 Adelstein DJ, Lavertu P, Saxton J et al.: mature results of a Phase III randomised trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck. Cancer88,876–882 (2000).
- 3 Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog.7,139 (1993).
- 4 Van Dyke DL, Worsham MJ, Bernninger MS et al.: Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer9,192 (1994).
- 5 Jares P, Fernandez PL, Campo E et al.: PRAD-1/cyclin D1 gene amplification correlates with messenger RNA over-expression and tumor pregression in human laryngeal carcinomas. Cancer Res.54,4813 (1994).
- 6 Okami K, Reed AL, Cairns P et al.: Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene18,3541 (1999).
- 7 Bromberg J, Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene19,2468–2473 (2000).
- 8 Song JI, Grandis JR: STAT signaling in head and neck cancer. Oncogene19,2489 (2000).
- 9 Grandis JR, Drenning SD, Zeng Q et al.: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.Proc. Natl Acad. Sci. USA97,4227–4232 (2000).
- 10 Nagatsuka H, Ishiwari Y, Tsujigiwa H et al.: Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol.37,599–604 (2001).
- 11 Lorimier IA: Mutant epidermal growth factor receptors as target for cancer therapy. Curr. Cancer Drug Targets2,91–102 (2002).
- 12 Rubin Grandis J, Tweardy DJ: Elevated levels of transforming growth factor-α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res.53,3579–3584 (1993).
- 13 Chen BK, Ohtsuki Y, Furihata M et al.: Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int. J. Oncol.15,893–898 (1999).
- 14 Ang KK, Berkey BA, Tu X et al.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62,7350–7356 (2002).
- 15 Numico G, Colantonio I, Comino A et al.: EGFR and survival of patients with locally advanced head and neck cancer (HNC) and treated with alternating chemotherapy radiation (CT-RT). Results of a retrospective analysis. Proc. Am. Soc. Clin. Oncol.22,2018 (2003) (Abstract 2018).
- 16 Rodrigo JP, Gonzalez MV, Lazo PS et al.: Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinico-pathological features. Oral Oncol.38,357 (2002).
- 17 Rubin Grandis J, Zeng Q, Tweardy DJ: Retinoic acid normalizes the increased gene transcription rate of TGF-α and EGFR in head and neck cancer cell lines. Nat. Med.2,237–240 (1996).
- 18 Crombet T, Torres O, Neninger E et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother. Radiopharm.16,93–102 (2001).
- 19 Medjtahedi H, Hickish T, Nicolson M et al.: Phase I trial and tumor localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer73,228–235 (1996).
- 20 Goldstein NI, Prewett M, Zuklys K et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human xenograft model. Clin. Cancer Res.1,1311–1318 (1995).
- 21 Wu X, Rubin M, Fan Z et al.: Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene12,1397–1403 (1996).
- 22 Robert F, Ezekiel MP, Spencer SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol.19,3234–3243 (2001).• First study of cetuximab in combination with radiotherapy (RT).
- 23 Baselga J, Pfister D, Cooper MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol.18,904–914 (2000).• Clinical trial demonstrating the activity of cetuximab in patients refractory to cisplatin.
- 24 Milas L, Mason K, Hunter N et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res.6,701–708 (2000).
- 25 Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res.59,1935–1940 (1999).
- 26 Pfister D, Su YB, Kraus DH et al.: Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot study of a new combined-modality paradigm. J. Clin. Oncol.24,1072–1078 (2006).• Recommended trial of cetuximab/cisplatin/RT with unexpected toxicity.
- 27 Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.353,567–578 (2006).•• First trial that demonstrated the efficacy of cetuximab/RT and supported the approval of cetuximab/RT by the US FDA and the European Agency for the Evaluation of Medicinal Products.
- 28 Forastiere AA, Metch B, Schuller DE et al.: Randomized comparison of cisplatin plus fuorouracil and carboplatin plus fluouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J. Clin. Oncol.10,1245–1251 (1992).• Oldest trial where methotrexate was considered the standard treatment in advanced head and neck cancer.
- 29 Leon X, Hitt R, Constela M et al.: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol.17,418–424 (2005).
- 30 Baselga J, Trigo JM, Bourhis J et al.: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.23,5568–5577 (2005).
- 31 Herbst RS, Arquette M, Shin DM et al.: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol.23,5578–5587 (2005).• Important trial that demonstrated the activity of cetuximab in refractory patients with advanced head and neck cancer.
- 32 Burtness B, Goldwasser MA, Flood W et al.: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.20,5440–5442 (2005).
